Clinical Trial News and Research

RSS

Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrome

Researchers at Moffitt Cancer Center and colleagues at six other institutions have recently tested a treatment for patients with myelodysplastic syndrome, or MDS, a blood-related malignancy that involves the ineffective production of blood cells, leaving patients anemic and in need of frequent blood transfusions. Because the body has no natural means to reduce iron that accumulates from repeated transfusions, patients' organs can become iron overloaded, leading to heart failure, liver injury, susceptibility to infection, and other complications.

23 Jun 2012

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

Weill Cornell Medical College researchers have devised an innovative boxer-like strategy, based on the serial use of two anti-cancer drugs, to deliver a one-two punch to first weaken the defenses of multiple myeloma and then deliver the final knock-out punch to win the fight.

23 Jun 2012

AbGenomics raises $11 million in current financing round

AbGenomics International announced today that it has raised $11 million in current financing round. It brings total investment in AbGenomics to approximately $52 million since its inception in 2000.

23 Jun 2012

FDA issues CRL to Repligen's RG1068 NDA for treatment of pancreatitis

Repligen Corporation today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for RG1068.

23 Jun 2012

Patients taking common blood pressure drug show symptoms of celiac disease

Mayo Clinic researchers have discovered an association between a commonly prescribed blood pressure drug, Olmesartan, and severe gastrointestinal issues such as nausea, vomiting, diarrhea, weight loss and electrolyte abnormalities -- symptoms common among those who have celiac disease. The findings are published online today in the medical journal Mayo Clinic Proceedings.

22 Jun 2012

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

22 Jun 2012

DBS can improve muscle symptoms in patients with Parkinson's

Patients with Parkinson's disease who undergo deep brain stimulation (DBS)—a treatment in which a pacemaker-like device sends pulses to electrodes implanted in the brain—can expect stable improvement in muscle symptoms for at least three years, according to a Department of Veterans Affairs study appearing in the most recent issue of the journal Neurology.

22 Jun 2012

FDA grants Orphan Drug Designation to Medgenics’ INFRADURE Biopump

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that its INFRADURE Biopump has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for the treatment of hepatitis D.

21 Jun 2012

e-Therapeutics commences enrollment in ETS2101 phase I trial for brain cancer

e-Therapeutics plc announces the start of the first clinical trial evaluating its compound ETS2101 as a treatment for cancer. The phase I trial is enrolling patients with primary brain cancer (glioma) or cancer that has spread to the brain from other sites.

19 Jun 2012

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

InnaVirVax, a biopharmaceutical company specialized in the research and development of therapeutic and diagnostic innovations focused on immune dysregulation, announced today that a new European patent application has been filed on VAC-3S, a “first-in-class” immunotherapy for the treatment of HIV infections.

19 Jun 2012

Antiarrhythmic short-term treatment useful for some patients

Atrial fibrillation (AF) is the most frequently sustained arrhythmia of the heart. It affects several million people in Europe. AF causes a loss of contraction in the atria and gives rise to heart failure. Moreover, it is associated with a high risk of stroke. One in five strokes is due to AF.

19 Jun 2012

ALung completes pilot study of Hemolung RAS in COPD patients

ALung Technologies, Inc., a leading developer of innovative lung assist devices, presented an analysis of its recent clinical trial of the Hemolung Respiratory Assist System (RAS) in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD).

19 Jun 2012

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

19 Jun 2012

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

Today Abbott announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease.

19 Jun 2012

Positive interim data from Innate MIS416 Phase 1/2 clinical trial for chronic progressive MS

Innate Immunotherapeutics today announced positive interim data from the company's Phase 1/2 clinical trial of MIS416 in patients with chronic progressive multiple sclerosis (MS).

18 Jun 2012

PAREXEL launches fully-integrated eClinical solution

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of the PAREXEL MyTrials platform, a fully-integrated eClinical solution that simplifies the clinical trial process.

From Parexel 18 Jun 2012

CINJ commences enrollment in three-drug combination trial for breast cancer

Researchers at The Cancer Institute of New Jersey (CINJ) are enrolling patients for a clinical trial, which aims to evaluate a new drug for breast cancer that has spread (metastatic) in combination with two chemotherapy agents called doxorubicin and cyclophosphamide.

18 Jun 2012

DBV Technologies’ Viaskin safe and effective in treating children with peanut allergy

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today that AP-HP (Assistance Public - Hôpitaux de Paris) sponsor of the ARACHILD study presented at the EAACI Congress a late breaking oral presentation on safety and efficacy data after six months of epicutaneous immunotherapy in peanut allergy using Viaskin Peanut.

18 Jun 2012

Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

The oral presentation will be held on June 17th 2012 by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam.

18 Jun 2012

Tobacco cessation must be included as part of standard clinical care for cancer patients

While tobacco use can significantly hamper cancer treatment, few cancer researchers are incorporating tobacco assessment into their clinical studies. That's the conclusion a group of investigators led by Graham Warren, MD, PhD, Assistant Professor in the Department of Radiation Medicine at Roswell Park Cancer Institute (RPCI), drew from a recent survey of cancer clinical trials.

16 Jun 2012

Clinical Trial News and Research

Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrome

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

AbGenomics raises $11 million in current financing round

FDA issues CRL to Repligen's RG1068 NDA for treatment of pancreatitis

Patients taking common blood pressure drug show symptoms of celiac disease

Janssen receives FDA complete response letter for XARELTO sNDA

DBS can improve muscle symptoms in patients with Parkinson's

FDA grants Orphan Drug Designation to Medgenics’ INFRADURE Biopump

e-Therapeutics commences enrollment in ETS2101 phase I trial for brain cancer

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

Antiarrhythmic short-term treatment useful for some patients

ALung completes pilot study of Hemolung RAS in COPD patients

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

Positive interim data from Innate MIS416 Phase 1/2 clinical trial for chronic progressive MS

PAREXEL launches fully-integrated eClinical solution

CINJ commences enrollment in three-drug combination trial for breast cancer

DBV Technologies’ Viaskin safe and effective in treating children with peanut allergy

Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

Tobacco cessation must be included as part of standard clinical care for cancer patients

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer